Status:
COMPLETED
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
To gather information on the safety of monotherapy of Casodex® tablets 80 mg, targeting prostate cancer patients who have no history of having received treatment by either endocrine therapy (including...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Prostate cancer patients who have no history of receiving endocrine therapy (including surgical castration), and who plan to undergo Casodex® tablets monotherapy for not less than 12 months
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
712 Patients enrolled
Trial Details
Trial ID
NCT00919477
Start Date
May 1 2009
End Date
March 1 2012
Last Update
January 23 2013
Active Locations (160)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Houmei, Aichi-ken, Japan
2
Research Site
Inuyama, Aichi-ken, Japan
3
Research Site
Kasugai, Aichi-ken, Japan
4
Research Site
Nagoya, Aichi-ken, Japan